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Abstract
Background: Alternative splicing events that result in the production of multiple gene isoforms reveals important
molecular mechanisms. Gene isoforms are often differentially expressed across organs and tissues, developmental
stages, and disease conditions. Specifically, recent studies show that aberrant regulation of alternative splicing
frequently occurs in cancer to affect tumor cell transformation and growth. While analysis of isoform expression is
important for discovering tumor-specific isoform signatures and interpreting relevant genomic mutations, there is
currently no web-based, easy-to-use, and publicly available platform for this purpose.
Description: We developed ISOexpresso to provide information regarding isoform existence and expression, which
can be grouped by cancer vs. normal conditions, cancer types, and tissue types. ISOexpresso implements two main
functions: First, the Isoform Expression View function creates visualizations for condition-specific RNA/isoform
expression patterns upon query of a gene of interest. With this function, users can easily determine the major isoform
(the most expressed isoform in a sample) of a gene with respect to the condition and check whether it matches the
known canonical isoform. ISOexpresso outputs expression levels of all known transcripts to check alterations of
expression landscape and to find potential tumor-specific isoforms. Second, the User Data Annotation function
supports annotation of genomic variants to determine the most plausible consequence of a variation (e.g., an amino
acid change) among many possible interpretations. As most coding sequence mutations are effective through the
subsequent transcription and translation, ISOexpresso automatically prioritizes transcripts that act as backbones for
mutation effect prediction by their relative expression. By employing ISOexpresso, we could investigate the
consistency between the most expressed and known canonical/principal isoforms, as well as infer candidate
tumor-specific isoforms based on their expression levels. In addition, we confirmed that ISOexpresso could easily
reproduce previously known isoform expression patterns: recurrent observation of a major isoform across tissues,
differential isoform expression patterns in a given tissue, and switching of major isoform during tumorigenesis.
Conclusions: ISOexpresso serves as a web-based, easy-to-use platform for isoform expression and alteration analysis
based on large-scale cancer database. We anticipate that ISOexpresso will expedite formulation and confirmation of
novel hypotheses by providing isoform-level perspectives on cancer research. The ISOexpresso database is available
online at http://wiki.tgilab.org/ISOexpresso/.
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Background
Alternative splicing occurs in most human genes with
multiple exons as a regulatory process of gene expres-
sion [1]. In this process, particular exons of a gene may
be included or excluded in the final processed mRNAs
to produce multiple distinct transcript isoforms, bring-
ing great diversity to human proteins [2]. To date, several
mechanisms for alternative splicing have been reported,
such as alternative promoters, exon skipping, mutually
exclusive exons, exon scrambling, alternative 5′ and 3′
splice sites, retained introns, and alternative polyadeny-
lation [1, 2]. Aberrant splicing patterns that are com-
monly observed in human cancers have been associated
with splicing regulators [2, 3]. For instance, dysregu-
lated expression of splicing regulators (e.g., RBFOX2,
PTB/PTBP1, and SRSF1 genes) has been reported to cause
splicing pattern changes in genes [3, 4].
The advent of whole transcriptome sequencing (RNA-
seq) and development of related bioinformatics analysis
tools have enabled us to observe not only the expression
snapshot of genes but also their sequences and structural
configurations. Particularly, several computational meth-
ods have successfully identified the presence of multiple
isoforms to reconstruct the composition of mixed tran-
scripts. RSEM [5] and eXpress [6] adopt ungapped align-
ment of reads to reference transcriptome and estimate
transcript abundance by the expectation-maximization
(EM) algorithm. Cufflinks [7] uses gapped (spliced) align-
ment against reference genome as an input to build the
overlap graph and to compute the minimum path cover
for estimating the presence and abundance of transcripts.
StringTie [8] performs read alignment with a procedure
similar to that of Cufflinks, builds flow network for path
with the heaviest coverage, and then computes maximum
flow to estimate the abundance of each transcript. Sail-
fish [9] employs an alignment-free approach using k-mer
indexed transcripts, and determines maximum likelihood
estimates of relative transcript abundance by counting the
indexed k-mers in the set of raw reads and applying the
EM algorithm. When applied to cancer, disease-specific
formation of alternative transcripts could be identified as
potential biomarkers for diagnosis [4, 10], cancer subtyp-
ing [11, 12], and tumor vaccine targets for immunothera-
peutics [10].
While the methodological robustness for isoform-level
analysis is being gradually improved, the demand for con-
venient applications to analyze cancer genomes remains,
particularly for large-scale databases. First, information
regarding isoform presence and expression is hardly cen-
tralized and visualized for easy access. Many online
expression databases such as TiGER [13], BioGPS [14],
BioXpress [15], and Gene Expression Atlas [16] allow
users to inspect genome-scale expression profiles at the
gene level. GeneFriends [17] and MIsoMine [18] are
the only databases that currently utilize transcript-level
expression information. However, GeneFriends is devel-
oped for the sole aim to identify co-expressed genes (and
transcripts), and MIsoMine provides tissue-specific iso-
form expression information only for mice. A more gener-
alized platform on which differential transcript expression
can be aggregated and compared across multiple tumor
tissues would serve as a valuable platform for hypoth-
esis formulation and testing. Second, nomenclature for
genes, transcript isoforms, and their relationships should
be carefully considered and handled, because inappro-
priate annotations often make simple questions far more
complicated. Determining how many isoforms exist in
a gene, which genomic regions are protein-coding, and
which transcript should be considered as the represen-
tative form are typical inherent problems in an isoform-
level analysis. Third, transcript expression information
can be utilized for interpreting genomic sequence vari-
ations. Conventional annotation of genomic mutations
usually outputs all possible amino acid changes with
respect to the known isoforms. When different isoforms
are considered, different consequences can be predicted
at the protein level. Once the major isoform is identi-
fied, we can resolve this ambiguity for more accurate
annotation.
To meet the demands, we developed ISOexpresso, a
web-based, graphical, and multi-purpose platform for
isoform-level analysis in cancer. ISOexpresso provides
isoform-level expression profiles for genes of interest and
creates visualizations with a convenient user interface,
such as expression statistics and chart display, thereby
helping users detect condition-specific isoform expres-
sion (e.g., tumor vs. normal). ISOexpresso is built upon
standard nomenclature used by many external databases
including the University of California Santa Cruz (UCSC)
table browser, the Consensus Coding Sequences (CCDS),
Ensembl, the Reference Sequence (RefSeq), and the Uni-
versal Protein Resource (UniProt), and efficiently har-
nesses useful information of different sources such as
biotype, known canonical isoform, genomic location,
and exon structure. ISOexpresso also provides isoform-
specific variant annotations prioritized by expression level
to predict the most plausible functional consequences
of the genomic mutations in the given sample. By using
ISOexpresso, we found that a significant number of non-
canonical isoforms were expressed in the cancer samples
to cause “switching” of major isoforms. In addition, we
could easily reproduce previous discoveries on cancer
isoform expression as a use-case of ISOexpresso. There-
fore, we anticipate that ISOexpresso will serve as a useful
web-based platform for researchers who are not bioin-
formaticians to collect, examine, test, and hypothesize
transcript-level changes in the tumorigenesis of various
cancers.
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Construction and content
ISOexpresso construction and implementation of functions
We constructed a web-based platform, ISOexpresso,
which implements two main functions, Isoform Expres-
sion View and User Data Annotation, by integrating pub-
licly available data and related information from various
databases (See below).
Data acquisition and preparation
RNA-seq data (level 3, RNA-seq v2 expression data)
and clinical information were obtained from The Can-
cer Genome Atlas (TCGA) Data Portal [19] for total
10,234 samples (9,499 tumors and 735 normal tissues)
of 30 cancer types (see Additional file 1: Table S1).
Tumor samples annotated as “primary solid tumor” and
“recurrent solid tumor,” and matched normal samples as
“solid tissue normal” were included in the 10,234 sam-
ples, whereas “metastatic” sample type was excluded. The
estimated fraction of transcripts made up by a given iso-
form or gene ranging from zero to one computed using
RSEM [5] was used to determine the statistical param-
eters (lower outliers, minimum, the first quartile (Q1),
median, the third quartile (Q3), maximum, and upper
outliers) for the expression levels of each gene and its
isoforms in each sample group. If two or more expres-
sion levels of gene or isoform were found for the same
patient, an averaged value was used in calculation of
the above parameters. Median transcripts per million
(TPM) was calculated by multiplying the median value
of the estimates in each sample group by one million,
which was then used to determine the major isoforms
in the given tissue and sample types. If median TPM
values of all isoforms of a gene were zero, Q3 values
were compared between them to determine the major
isoform.
Gene and isoform information
ISOexpresso basically follows gene and isoform def-
initions from UCSC Annotation database. At first,
corresponding gene and isoform lists based on the
hg19/GRCh37 reference genome were downloaded from
the database (refGene.txt.gz, knownCanonical.txt.gz,
knownGeneTxPep.txt.gz, and knownGene.txt.gz [20]).
UniProt Retrieve/ID mapping page (idmapping.dat.gz
[21]) was used for cross-referencing gene and isoform
IDs among different annotation databases that pro-
vide their own specialized information, which included
UniProt release 2015_08, RefSeq release 71, Ensembl
release 74, and CCDS release 19. HUGO Gene Nom
enclature Committee (HGNC) was used to enrich
gene function annotation and to support the search
module (i.e. searching with gene symbol, RefSeq ID,
UniProt ID, Ensemble gene ID, and UCSC isoform
ID [22]).
For most known genes, one to several isoforms
have been regarded as representative of the normal
state. Two main definitions are used in ISOex-
presso. One is the “principal” isoform defined by the
annotating principal splice isoforms (APPRIS) web
database, which has been constructed by integrating
protein structural information, functionally important
residues, and evidence from cross-species alignments
[23]. We downloaded the hg19/GRCh37 version
(appris_data.principal.txt [24]) to annotate the corre-
sponding isoforms. The other is the “canonical” isoform
defined by the UniProt and UCSC Annotation databases.
The UniProt-based canonical isoform is determined by
considering all the protein products encoded by a gene
for an isoform that satisfies at least one of the following
criteria: i) it is the most prevalent; ii) it is most similar
to orthologous sequences found in other species; iii)
by virtue of its length or amino acid composition, it
allows the clearest description of domains, isoforms,
polymorphisms, and post-translational modifications.
If no relevant information is available, the longest
sequence is selected [25]. The UCSC-based canonical
isoform can be identified in the knownCanonical.txt.gz
file for each gene, which is generally the longest
isoform [26].
Inference of tumor-specific isoforms
We implemented an inference module to help users iden-
tify tumor-specific isoforms that are only present or sig-
nificantly over-expressed in tumors. It should be noted
that since there are no consensus criteria on the inference
methodology, this module is intended for supplemental
use only. We considered two types of candidate tumor-
specific isoforms. Type I includes the isoforms that are
expressed in tumor samples but absent in the match-
ing normal samples. To determine the expression status
(expressed or unexpressed), we used a minimum thresh-
old of median TPM > 10−6, as used by Barrett et al. [10].
Type I candidates are further subdivided into two classes,
strong and weak, where the median TPM value and the
expression percentage of a strong candidate are greater
than or equal to 1.0 and 10%, respectively. Type II can-
didates are isoforms that are identified to be major in the
tumor but not in the matching normal sample with a suffi-
cient (median TPM fold change> 2) change in expression
level.
Database construction, web deployment, and user interface
ISOexpresso uses MySQL (version 5) to store prepro-
cessed expression levels of genes and isoforms as well
as information gathered from public databases and web
pages. It was developed using PHP language (version 5)
and deployed onto web using Apache HTTP server (ver-
sion 2.0). JavaScript and Highcharts [27] written in pure
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JavaScript were used for convenient user interface in
ISOexpresso.
Data analysis and applications
Consistency betweenmajor and canonical/principal isoforms
Among the 30 TCGA cancer types, 16 types for which 10
or more normal samples each were available were used for
analysis. We selected one major isoform for each of the
26,541 genes based on the calculated isoform expression.
Preselected canonical and principal isoforms (See Meth-
ods, Gene and isoform information) were compared to the
major isoform for a consistency check. For each cancer
type, the numbers of “matches” (the major isoform is the
canonical/principal isoform) and “mismatches” were cal-
culated using a custom Perl script (the script is available
upon request). It should be noted that only the genes hav-
ing at least one isoform with median TPM value greater
than zero were included in the consistency check.
Variability of mutation consequence annotation
We applied the ISOexpresso User Data Annotation func-
tion to annotate major isoform for 144,160 somatic
variants (VCF) called from 376 TCGA stomach adeno-
carcinoma (STAD) samples. Based on the annotation,
we examined the possible discrepancies in predicting the
consequence (alteration at the protein level) of eachmuta-
tion when different transcript backbones were considered:
expression-independent canonical/principal isoform vs.
the major isoform. Using the downloaded VCF file, we
first identified the genes at the chromosomal positions
with sequence variations, and then determined the major
isoform for each gene. Next, we checked the presence of
mismatch between the major isoform and the available
canonical/principal isoforms. For mismatched cases, we
identified the position of each variant at the structural
level of the transcripts, including exon (E), intron (I), 5′ or
3′ untranslated region (5U or 3U), or outside of transcript
region (OTR). If a variant was located in an exon or intron,
the number indicating the order of exons or introns from
the transcription start site was also used to represent the
variant location.We grouped the cases by comparing vari-
ant location in the major isoform and canonical/principal
isoforms. For the five most frequently observed cases,
we further investigated whether variant annotation at the
protein level was changed when the major isoform was
used instead of the canonical isoform.
Utility
We implemented ISOexpresso with two main func-
tions. First, ISOexpresso retrieves gene isoforms and
their expression profiles for a given condition (Isoform
Expression View function). In this function, users can
query a gene of interest to find its known isoforms
with annotations, check the most expressed isoform (the
major isoform), compare expression profiles among dif-
ferent sample groups, and finally determine the condition-
specific isoforms. Second, ISOexpresso automatically
annotates a given mutation list (VCF) with matching
isoform expression data to help users select a specific
transcript for predicting the functional effects of the
mutations (User Data Annotation function). By employ-
ing ISOexpresso, we further analyzed over 10,000 TCGA
samples to showcase its practical use in inspecting tissue-
and disease-specific isoforms, and the effects of transcript
variability in mutation interpretation.
Overall workflow of ISOexpresso
The overall workflow from user query to data output and
visualization is shown in Fig. 1. When given a gene name
with tissue information, ISOexpresso attempts to find a
matched gene from three nomenclature tables (HGNC
gene, Ensembl release 74, and UCSC refGene). Known
isoform information of the gene is then collected from
UniProt ID mapping data and UCSC knownGene. To
determine whether the retrieved isoforms are protein-
coding, ISOexpresso checks the availability of amino acid
sequence information in the UCSC (knownGeneTxPep)
table.
RNA expression levels of the matched gene and iso-
forms are extracted from prebuilt internal tables (con-
structed during the data acquisition step), which contain
pre-calculated statistical data for each group (normal or
tumor). These values are then processed for visualization
using a box plot and stacked column chart. ISOexpresso
selects the major isoform that is most expressed under
a given condition (individual sample or disease/tissue
group), and presents it along with the known canonical
and principal isoforms for comparison. Finally, candi-
date tumor-specific isoforms are inferred based on the
expression patterns.
Visualization of isoform expression
The overall summary of the Isoform Expression View is
illustrated in Figs. 2 and 3. To start a new session, users
have to submit their queries consisting of two types of
information: tissue(s) and a gene of interest (Fig. 2a).
Gene information may be provided in one of the fol-
lowing formats: gene symbol (e.g., FOXM1), gene name
(e.g., Forkhead box M1), chromosomal location (e.g.,
chr12:2966847-2986206), RefSeq ID (e.g., NM_202002),
UniProt ID (e.g., Q08050), or Ensembl gene ID (e.g.,
ENSG00000111206). Both keyword search and exact
match modes are available. Based on the user query,
the Isoform Expression View function outputs summary
information and detailed results in a separate panel
(Fig. 2b). Summary information shows the canonical iso-
forms (UniProt-based and UCSC-based) and the APPRIS
principal isoform (Fig. 2b-1) together with the most
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Fig. 1 Overall workflow of ISOexpresso. Gene information is first determined by using user-provided query (tissue and gene). Isoform information,
gene- and isoform-level RNA expression data, canonical and principal isoforms, and the major isoform are then obtained by searching
corresponding database tables. Two functions of ISOexpresso (Isoform Expression View and User Data Annotation) are operated by this workflow
expressed isoform (the major isoform) in the selected tis-
sues (Fig. 2b-2). Here, users can quickly compare whether
there is expression of any unexpected isoform. Detailed
results display the selected gene list (Fig. 2b-3) and basic
gene information (Fig. 2b-4). Expression at the gene level
is compared between the selected tumor groups and visu-
alized by a box plot (Fig. 2b-5). Next, a list of isoforms
and their annotations are shown in a table to provide
biotype (e.g. protein-coding), canonical and/or principal
information, matching UniProt ID, RefSeq ID, Ensembl
transcript ID, CCDS ID, and genomic coordinate (e.g.
chr12:2966846-2986321), number of exons, and the length
of each transcript (Fig. 2b-6). Exon structures of the iso-
forms are then visualized in a separate table (Fig. 2b-7),
depicting protein-coding regions, 5′ and 3′ untranslated
regions (UTRs), and introns. To visualize isoform-level
expression and to compare the expression pattern across
the selected tumors, ISOexpresso provides two additional
graphic panels (Fig. 2b-8 and 9). First, the absolute expres-
sion levels (TPM) of all isoforms are presented in stacked
column charts grouped by the selected tumor types. In
the example provided in Fig. 2b-8, five known isoforms
of the FOXM1 gene (uc001qle.3, uc001qlf.3, uc009zea.3,
uc009zeb.3, and uc001qlg.3) are expressed in three can-
cer types (BRCA, LUAD, and PRAD). Based on the chart,
one can easily determine that the known canonical iso-
form, uc001qlf.3, is the major isoform in all three can-
cer types, while a non-canonical isoform, uc009zeb.3 is
also expressed at high levels. Furthermore, two addi-
tional isoforms are expressed at low levels in two cancer
types (uc001qle.3 in BRCA and LUAD, and uc009zea.3
in BRCA). Following the grouped analysis, additional box
plots are shown (Fig. 2b-9, only BRCA is shown here as an
example) for each cancer type to visualize isoform-level
expression. Users can easily check statistical parameters
such as min, max, Q1, Q3, and median for further com-
parison within a cancer type. In addition, all the exact
values are automatically presented in a hover box upon
a mouseover event, and active URL link is supported for
all database IDs (UCSC, UniProt, RefSeq, Ensembl, and
CCDS) of the corresponding gene and its isoforms for
users’ convenience. Furthermore, users can download Iso-
form Expression View results as tab-delimited text file by
clicking a button of “Download Isoform Expression View
results” that is located in the top-right side of detailed
results (upper side of Fig. 2b-4), which information may
be useful for integrating into pipelines or combining with
results from other programs.
Finding tumor-specific isoforms
ISOexpresso provides a simple module for searching iso-
forms that are conditionally expressed in cancer or normal
samples (see Methods for detailed procedure). To enable
this module, users have to select only one cancer typewith ≥
10 matched normal samples, and to check the “Normal-
tumor comparison” mode in the query page (Fig. 2a, red
arrow). Given an appropriate query, ISOexpresso shows
one additional table in the standard visualization page
(immediately below the summary information) that con-
tains the result of the tumor -specific isoform analysis.
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Fig. 2 An example of using the Isoform Expression View function. a Start page, in which users can select one or more tissues and provide a gene to
be searched. b Result page is consisted of i) summary information and ii) detailed results. Summary information shows canonical and principal
isoforms of the gene (no. 1) and major isoforms for the selected tissues (cancer types; no. 2), in which two “U” squares in purple and green
background mean that corresponding major isoforms are matched to UniProt-based and UCSC canonical isoforms, respectively, and a “A” square in
orange background represent that the major isoform is identical with APPRIS principal isoform. Detailed results include gene list (no. 3), gene
information (no. 4), gene expression level represented by box plot (no. 5), isoform information (no. 6), exon structure of each isoform (no. 7), ratio of
isoform expression levels represented by stacked column chart (no. 8), and isoform expression levels represented by box plot (no. 9)
An example is shown in Fig. 3. The table mainly shows a
list of isoforms of the gene of interest, expression levels
of each isoform in normal and tumor samples (in TPM),
TPM-based fold changes, and provisional decisions on
cancer specificity. We currently use two distinct criteria
to annotate cancer specificity: one is the cancer-specific
expression (only expressed in cancer, absent in normal,
marked as Type I), and the other is the switch of the major
isoform (most expressed in cancer but not in normal tis-
sue, marked as Type II; see Methods for details). In the
given example, uc001qle.3 is a Type I candidate, as it is
expressed at approximately 0.40 TPM in the tumor and is
absent in the normal samples. It is further classified as the
“weak” type due to its low expression level in the tumor (<
1.0 TPM and (< 10% of overall expression in the tumor).
Likewise, uc001qlf.3 is a Type II candidate, because it is
the major isoform only in cancer (66.4%), while another
isoform (uc009zeb.3) is the major isoform in the normal
samples (77.6%). As there is no consensus on the exact
definition of tumor -specific isoform, we would like to
note that additional information such as sample number,
fold change, and gene function should be considered for
users’ final decision. Nevertheless, ISOexpresso provides
useful information for generating an initial hypothesis for
the designated purpose.
Mutation annotation for isoform-specific interpretation
Sequence variations in DNA usually affect phenotypes
through changing amino acid sequences of proteins. In
most cases, single nucleotide variant is interpreted into
the corresponding amino acid change in a straightfor-
ward manner using a representative (canonical) transcript
sequence. However, the consequence of variant can be
dramatically changed if isoforms of different structures
are considered, particularly when non-canonical isoforms
are the major ones in a sample. We noted that the con-
sequence of each DNA mutation must be interpreted
with respect to the isoform-level expression profile for
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Fig. 3 An example of inferring candidate tumor-specific isoform. This figure shows the comparison of isoform expression levels of FOXM1 between
normal and tumor tissues in the LUAD cancer type. Two types of candidate tumor-specific isoforms are observed: the first isoform, uc001qle.3, is
identified as a Type I (weak) candidate, and the second isoform, uc001qlf.3, is detected as a Type II candidate due to the switch of major isoform
under tumor condition with a median-based fold change of 29.3-fold upregulation
more accurate analysis. ISOexpresso provides the User
Data Annotation function for this purpose. The User Data
Annotation function can be run by simply selecting a tis-
sue type with a user-uploaded variant list (VCF). When
given a query, ISOexpresso outputs a newly annotated
VCF with a downloadable link.
An example of results produced by this function is
shown in Fig. 4a. In the output VCF file, nine novel fields
are newly created (Fig. 4a, blue asterisk). These include 1)
sample tissue (IE_TS), 2) cancer type considered for iso-
form expression (IE_CA), 3) sample type (IE_SA, tumor or
normal), 4) the number of samples (IE_SN), 5) gene sym-
bol at the mutation site (IE_GE), 6) UniProt-based canon-
ical isoform (IE_UP), 7) UCSC-based canonical isoform
(IE_UC), 8) APPIRS-based principal isoform (IE_AP), and
9) an isoform list sorted by expression level in the cor-
responding cancer type (IE_IS). Among them, the first
four fields (IE_TS, IE_CA, IE_SA, and IE_SN) are directly
annotated in the VCF header area, and the others (IE_GE,
IE_UP, IE_UC, IE_AP, and IE_IS) are written in the entry
of each variant (Fig. 4a, red arrow). For each isoform in the
sorted isoform list (IE_IS), further information is included
such as biotype (e.g. protein-coding), genetic elements at
the position (e.g. E2: exon 2, I7: intron 7, 5U: 5′-UTR,
3U: 3′-UTR, and OTR: outside of transcription region),
median TPM value of the isoform, and cross-reference
database IDs including UniProt, RefSeq, Ensembl, and
CCDS. With the sorted list, users can select the isoform
that will be used for variant annotation (see Additional
file 2: Figure S1).
We present several representative cases from TCGA
data, in which isoform expression information is consid-
ered for variant annotation (Fig. 4b). In case 1, amino acid
change is not altered (Ser to Ser), despite that the major
isoform is not canonical. In case 2, the coding region of
the T>C variant of BTF3L4 is different (exon 3 vs. 4)
when considering the major isoform (uc010onh.2) and the
canonical isoform (uc001ctk.3). While the former results
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Fig. 4 Example of a result page produced by the User Data Annotation function. a Output VCF file generated by the function, in which 9 information
fields are newly added as indicated by the blue asterisk. bMost frequently observed cases when compared mutation consequences between major
and canonical/principal isoforms using somatic mutations of TCGA STAD data. For each case, the TCGA sample barcode, gene symbol, chromosomal
location, base change, and respective amino acid changes in the major and canonical isoforms are shown
in an amino acid change from Leu to Ser, the latter is inter-
preted as a synonymous mutation. In case 3, the G>A
mutation in AMHR2 is interpreted as an Arg to Gln alter-
ation in the canonical isoform (uc001scx.2), but it lies in
the 3′-UTR region when the major isoform (uc009zmy.2)
is considered. Likewise, cases 4 to 6 show that mutations
can be interpreted in different ways, such as synonymous
or non-synonymous mutation vs. non-coding mutations
(intron, UTR, or OTR), depending on the isoform struc-
ture of the major transcript. We will show that a great
number of variants are interpretable in different ways and
they fall into one of the six cases (see Application 3).
Application 1: Correspondence between the major and the
canonical isoforms
As a case study, we inspected the overall consistency
between the major isoforms and the canonical/principal
isoforms in cancer (Table 1 and Additional file 3:
Table S2). We examined the isoform expression levels of
26,541 genes from 15 cancer types under both normal and
tumor conditions. For each cancer type, only expressed
genes (median TPM > 0) were used for analysis (17,532–
19,526 genes, 66.1–73.6% of 26,541). In approximately
12% of the expressed genes (1,867–2,547), no canonical or
principal isoforms were defined. In the remaining genes
(expression level is > 0 and canonical/principal isoform
is defined), we tested whether the canonical/principal
isoforms were the most expressed. Surprisingly, we found
that the canonical/principal isoform matched the major
isoform in only approximately 70% (67.7–76.3%) of the
genes. In other words, non-canonical isoforms were more
highly expressed in approximately 30% of the genes
(23.7–32.2%).
We postulate two reasons for the unexpectedly high
expression of non-canonical isoforms. First, the expres-
sion levels or prevalence of isoforms is only part of the
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Table 1 Statistics for the match and mismatch between major and canonical (or principal) isoforms
No. of genes (n=26541)
Cancer types No. of samples mTPM>0 Percent increaseb
mTPM=0
Matcheda Not matched
kCanon nokCanon
KIRP_normal 32 7359 12721 (2438)c 3972 (1113) 2489 (1594)
KIRP_tumor 290 8089 11544 (2474) 4580 (1266) 2328 (1475) 15.3%
COAD_normal 41 7751 12562 (2543) 3919 (1189) 2309 (1597)
COAD_tumor 460 8234 11805 (2442) 4291 (1298) 2211 (1443) 9.5%
THCA_normal 59 7647 12389 (2363) 4019 (1071) 2486 (1489)
THCA_tumor 505 7964 11838 (2405) 4387 (1166) 2352 (1504) 9.2%
PRAD_normal 52 7429 12546 (2493) 4104 (1077) 2462 (1565)
PRAD_tumor 497 7645 12042 (2549) 4445 (1228) 2409 (1523) 8.3%
READ_normal 10 7402 12743 (2451) 3954 (1152) 2442 (1686)
READ_tumor 165 8140 11879 (2499) 4283 (1277) 2239 (1459) 8.3%
UCEC_normal 35 7715 11641 (2284) 4763 (1191) 2422 (1518)
UCEC_tumor 545 7746 11226 (2515) 5152 (1323) 2417 (1551) 8.2%
BLCA_normal 19 7986 11820 (2373) 4433 (1206) 2302 (1577)
BLCA_tumor 408 8057 11381 (2541) 4791 (1412) 2312 (1593) 8.1%
KIRC_normal 72 7411 12712 (2423) 3941 (1098) 2477 (1604)
KIRC_tumor 533 7623 12166 (2387) 4240 (1174) 2512 (1627) 7.6%
LUSC_normal 51 7251 12681 (2415) 4055 (1058) 2554 (1702)
LUSC_tumor 502 7350 12404 (2563) 4300 (1187) 2487 (1670) 6%
STAD_normal 35 7866 12901 (2559) 3443 (1151) 2331 (1663)
STAD_tumor 415 7374 13017 (2520) 3608 (1196) 2542 (1723) 4.8%
HNSC_normal 44 7831 12622 (3040) 3844 (1225) 2244 (1678)
HNSC_tumor 520 7881 12383 (2788) 3994 (1193) 2283 (1626) 3.9%
LUAD_normal 59 7802 12228 (2185) 4146 (1069) 2365 (1533)
LUAD_tumor 516 7547 12263 (2401) 4274 (1163) 2457 (1622) 3.1%
KICH_normal 25 7166 12787 (2420) 4020 (1098) 2568 (1599)
KICH_tumor 66 8362 11776 (2773) 4146 (1368) 2257 (1529) 3.1%
LIHC_normal 50 9136 10714 (3129) 4786 (1963) 1905 (1504)
LIHC_tumor 370 8787 10782 (2860) 4907 (1769) 2065 (1534) 2.5%
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Table 1 Statistics for the match and mismatch between major and canonical (or principal) isoforms (Continued)
BRCA_normal 114 7396 12504 (2193) 4107 (1025) 2534 (1559)
BRCA_tumor 1097 7711 12224 (2378) 4190 (1162) 2416 (1575) 2%
ESCA_normal 11 7544 12824 (2847) 3701 (1306) 2472 (1772)
ESCA_tumor 184 7136 13037 (2639) 3754 (1201) 2614 (1739) 1.4%
aThe number of genes whose major isoform is matched to at least one of UniProt-based and UCSC-based canonical and APPRIS principal isoforms
bPercent increase in the number of genes corresponding to “kCanon” when condition is changed from normal to tumor
cThe numbers in parentheses indicate the number of genes whose expression level (mTPM) is greater than or equal to 1
mTPM = median transcripts per million
kCanon = the genes whose canonical or principal isoform is known
nokCanon = the genes whose canonical or principal isoform is not known
factors that define canonical and principal isoforms. In
many cases, sequence conservation, length, expression or
description clarity of domains or posttranslational mod-
ifications are also considered [28]. For these genes, the
canonical or principal isoforms are not necessarily the
most highly expressed. Second, there may be an actual
change in isoform expression pattern under the specific
condition. We found that the number of cases with non-
canonical major isoforms was higher in the tumor than
in the normal samples (Table 1 and Additional file 3:
Table S2). In all 15 cancer types, the increase was con-
sistently observed, ranging from 1.4 to 11.5% (64 to 568
genes). Such result indicates that there may be aberrant
expression of isoforms in cancer.
Application 2: Rediscovery of unusual isoform expression
patterns
In the majority of cases, the canonical isoforms are
expected to be predominantly expressed across differ-
ent tissues and conditions. However, there are also many
unusual cases in which isoform expression does not fol-
low the expected pattern. We tested whether ISOex-
presso can showcase such unusual patterns reported by
previous studies. Three genes that are known to show
distinct isoform expression patterns were selected for
ISOexpresso analysis. First, CD47 is a transmembrane
protein that participates in a wide range of cellular process
including apoptosis, proliferation, adhesion, and migra-
tion [29]. CD47 has been reported as a gene for which
non-canonical isoform (ENST00000361309; uc003dwt.1)
is predominantly and recurrently expressed in 16 tis-
sues (adipose, adrenal, brain, breast, colon, heart, kid-
ney, liver, lung, lymph node, ovary, prostate, skeletal
muscle, testes, thyroid, and white blood cells) [30]. We
could quickly confirm such pattern in 15 different tis-
sues using the ISOexpresso Expression View function,
five of which have not been reported previously (bladder,
uterus, esophagus, head/neck, and stomach, Fig. 5a). The
major (uc003dwv.1) and canonical (uc003dwt.1) isoforms
were also readily identified. Second, we inspected the
FBLN2 gene that encodes an extracellular matrix protein
with tumor-suppressive function [31]. A switch of major
isoform during tumorigenesis has been reported [32],
which was clearly demonstrated in ISOexpresso (Fig. 5b).
Among the four known isoforms, two isoforms showed
dramatic expression shift: from uc011ava.2 to uc011avb.2
in nine cancer types (Fig. 5b, red asterisks). For the third
example, CD44 is a cell surface glycoprotein that plays
crucial roles in development as well as in cancer progres-
sion and metastasis [33, 34], whose isoforms are known
to be differentially expressed across tissues in many vari-
ant forms [35–37]. As expected, the expression pattern
was reproduced in ISOexpresso (Fig. 5c). Thirteen of 15
normal tissues revealed that major type was an isoform,
uc001mvx.3 (left chart of Fig. 5c). By contrast, one of three
isoforms (uc001mvv.3, uc001mvw.3, or uc001mvx.3) was
expressed as major type in tumor tissues (right chart of
Fig. 5c). In addition,CD44 also showed that major isoform
switching was found in 7 tumor tissues during tumori-
genesis represented as asterisks in right chart of Fig. 5b,
showing heterogeneous expression of CD44 isoforms by
aberrant RNA splicing in tumor.
Application 3: Variability in mutation interpretation
We determined the extent to which DNA variation is
subject to altered interpretation when different isoform
structures were considered. We analyzed 147,540 somatic
mutations called from TCGA STAD data with the ISOex-
presso User Data Annotation function. By using UCSC-
based canonical isoforms, we found 27,655 mutations
for which the major isoform was not canonical (see
Additional file 4: Figure S2). Among them, 25,544 (92.4%
of 27,655) were located in coding regions with respect to
the canonical isoform structures.
We further inspected the possible alteration in interpre-
tation of the 25,544 mutations by changing the backbone
structure to the major isoform. We found that 21,599
(84.6% of 25,544) mutations were still located in coding
regions. Among the remaining 3,945 (15.4%) mutations,
1,308 (5.1%), 492 (1.9%), and 2,145 (8.4%) were located in
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Fig. 5 Isoform expression patterns that have been reported by
previous studies. a The non-canonical major isoform (uc003dwv.1,
blue) of CD47 is predominantly expressed in most of normal tissues
compared to the canonical isoform (uc003dwt.1, lime). b FBLN2
(fibulin 2) exhibits switching of the major isoform (uc011ava.2, blue
and uc011avb.2, cyan) between normal and tumor tissues. c Differential
expression patterns of CD44 isoforms is shown across tissues, where
one of the isoforms (uc001mvv.3, uc001mvw.3, or uc001mvx.3) is
highly expressed as a major type in each tissue. In addition, major
isoform switching during tumorigenesis was also found as represented
by red asterisks
intronic, 5′ UTR, and 3′ UTR regions of themajor isoform,
respectively. Therefore, consequences of these mutations
were drastically changed when the major isoforms were
considered for interpretation. Among the 21,599 muta-
tions that were located in both the canonical and major
isoforms, 9,373 (43.4% of 21,599) were not accompanied
by a change in exon number (as shown in Fig. 4b, case 1).
Consistent with this, the amino acid residue for each
mutation was predicted to be the same as that in themajor
isoform. In the other 12,226 mutations, exon number was
changed (as shown in Fig. 4b, case 2). Among them, only
743 (0.6% of 12,226) mutations that caused alteration in
amino acid residue were interpreted to different amino
acid; even the exon number has been changed, amino acid
sequence is unaffected in translation if the reading frame
was retained. We performed similar analyses using differ-
ent definitions of canonical or principal isoform (UniProt
andAPPRIS), and produced similar results (see Additional
file 4: Figures S3, S4).
Discussion
ISOexpresso is designed to facilitate expression-based
isoform-level analysis in cancer. To achieve this, RNA-
seq data sets of 30 cancer types were collected from
TCGA, which is a publicly available large-scale data
source. ISOexpresso implements two main functions:,
Isoform Expression View and User Data Annotation. The
first function focuses on delivering condition- or tissue-
specific isoform expression patterns (Fig. 2b), which
enables detection of the major isoform in a given tissue,
inspection of match or mismatch between the major and
canonical isoforms, and provides visualization of differen-
tially expressed genes and isoforms across distinct condi-
tions or tissues. This function allows us to observe three
different isoform expression patterns as described earlier
(Fig. 5): i) recurrently observed major isoform across the
tissues, ii) differentially expressed isoforms across the tis-
sues, and iii) major isoform switching between normal
and tumor conditions. Some of the isoforms correspond-
ing to the second or third case may reflect characteristics
of certain states of samples and can have potential as
biomarkers for diagnosis [4, 10], cancer subtyping [11, 12],
and tumor vaccine targets for immunotherapeutics [10].
For this purpose, we included a simple inference module
in ISOexpresso for determining tumor-specific isoforms
based on relative isoform expression between normal and
tumor conditions, as shown in Fig. 3. The second func-
tion was implemented to offer annotation results of user-
provided variants via expression-based prioritization of
gene isoforms, thereby helping users to predict the effects
of the variants. Figure 4b shows that isoform expres-
sion can be attributed as an influencing factor on variant
effect prediction, where variant annotations in cases 2–6
were changed when using major isoforms instead of the
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canonical ones. In particular, case 2 reveals that a single
variant can produce different results depending on which
isoform is used as the reference for variant annotation:
nonsynonymous missense mutation (leucine to serine) in
the major isoform vs. synonymous mutation (isoleucine
to isoleucine) in the canonical isoform. The above exam-
ples clearly demonstrate the usefulness and application of
ISOexpresso in expression-based isoform-level analysis.
ISOexpresso allowed us to show the overall landscape
for whether the major isoform of each gene matched
the known canonical (or principal) isoform in normal
and tumor tissues. Although the occurrence was low and
the numbers varied depending onto the cancer types, we
could observe a trend that the number of genes expressed
as non-canonical major isoforms is increased by tumori-
genesis as shown in Additional file 3: Table S2. This is
clear evidence demonstrating the presence of differen-
tially expressed isoforms and major isoform switching
between normal and tumor tissues. As reported by pre-
vious studies [2, 3], cancer is closely associated with
aberrant regulation of alternative splicing and therefore to
the production of non-canonical and tumor-specific iso-
forms. Among the switched major isoforms in tumors,
if their median TPM-based fold changes were greater
than or equal to 2-fold compared to the normal sam-
ples, the isoforms were considered as Type II candidate
tumor-specific isoforms, such as the second isoform in
Fig. 3. Therefore, the overall survey revealed that ISOex-
presso represents a useful tool to help discover candidate
tumor-specific isoforms in various cancer types.
Several variant annotation tools are currently available,
such as VEP [38], ANNOVAR [39], SeatleSeq [40], and
snpEff [41]. The programs provide users with mainly
mutation-oriented information such as nucleotide and
amino acid changes corresponding to the sequence vari-
ations and mutation types (e.g., missense, nonsense).
Although all transcripts are considered for variant anno-
tation, there is no criterion to prioritize certain tran-
scripts for predicting variant consequences. The User
Data Annotation function of ISOexpresso prioritizes iso-
forms based on their relative expression levels, thereby
helping users select an appropriate isoform for effective
variant annotation. In addition, it provides not only the
biotype of each isoform that enables the user to distin-
guish whether the particular isoform is protein-coding,
but also known isoform IDs from several databases that
make it possible to utilize previously annotated results
using other tools. This additional information also helps
the user select the most plausible isoform with functional
consequence. Furthermore, it is possible to assist clini-
cians in making decisions by identifying the variant that is
critical for patient treatment.
Regarding Isoform-level expression analysis, we
searched currently available programs using RNA-seq
data as following: Alt Event Finder [42], ARH-seq [43],
ASprofile [44], DiffSplice [45], FDM [46], MATS [47],
SplicingCompass [48], and SpliceSeq [49] for identifying
transcripts that produced by alternative splicing in a gene
or expressed as differential spliced forms between sam-
ples or conditions; RSEM [5], eXpress [6], Cufflinks [7],
StringTie [8], and Sailfish [9] for estimating their expres-
sion level at transcript level; and Cuffdiff [7], EBSeq [50],
rSeqDiff [51], and Ballgown [52] for extracting differen-
tially regulated transcripts according to the condition
change. For the purpose, it may be needed appropriate
selection and combinational use of the programs. Among
them, SpliceSeq has similar functions with ISOexpresso’s
ones, which enables to support tabular and graphical
visualization of transcripts and comparison between
sample groups using SpliceSeq Viewer, and also uses a
database system for storing and visualizing RNA-seq data
of which the analysis is already completed. Moreover,
the program allows users to analyze raw sequence data
by using SpliceSeq Analyzer. Accordingly, SpliceSeq
may also be appropriate for isoform-level RNA-seq data
analysis. Nevertheless, we expect that ISOexpresso may
be more specified for cancer genome research compared
to SpliceSeq, since it allows users to provide isoform
expression data for multiple cancer types based on large-
scale cancer database (TCGA). In addition, any users can
access ISOexpresso to extract information regarding iso-
form existence and expression, since it allows anonymous
access on the web.
TCGA is a project aimed to study the DNA and RNA
of multiple cancer types, and it releases publicly avail-
able high throughput sequencing data. TCGA data have
been incorporated into recent studies. However, several
cancer types have few or no matched normal tissue sam-
ples. The comparison between normal and tumor samples
is restricted if only TCGA data sets are used. A project
named the Genotype-Tissue Expression (GTEx) aims to
provide the scientific community with a resource to study
human gene expression and regulation, and their relation-
ships with genetic variations [53]. The GTEx also releases
all project data through the database of Genotypes and
Phenotypes (dbGaP [54]), and summary data on the GTEx
portal. These expression data from normal tissues will be
incorporated into our ISOexpresso database in the near
future. Therefore, we expect that it will be possible to
reliably present candidate tumor-specific isoforms upon
obtaining sufficient amounts of expression data in normal
tissues.
Data update is a crucial issue for maintaining a database.
TCGA data sets have updated and released on TCGA
Data Portal. Accordingly, update of data sets included in
ISOexpresso database should be performed for mainte-
nance of newly released data. We have a plan of regular
data update quarterly. This work also contains gradual
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conversion of gene and isoform expression data based on
new version of reference genome (Hg38/GRCh38) instead
of Hg19/GRCh37 version. Moreover, uploading and pro-
cessing of user’s own expression data generated from
RSEM will be supported in the near future, which may be
a useful ISOexpresso function for researcher. Therefore,
isoform-level analysis in ISOexpresso will be achieved by
providing newly updated TCGA data and by supporting
analysis from user’s own data.
Conclusion
ISOexpresso was designed to facilitate expression-based
isoform-level analysis of large-scale TCGA multi-cancer
RNA-seq data. There are two main functions in ISOex-
presso: i) the Isoform Expression View function focus-
ing on delivering condition- and tissue-specific isoform
expression levels and ii) the User Data Annotation func-
tion prioritizing variants based on their relative expres-
sion levels to help predict the most plausible functional
variant. We also confirmed that the ISOexpresso func-
tions could reproduce the results reported by previous
studies. Therefore, ISOexpresso will be a useful web-
based platform for isoform-level analysis in cancer.
Availability and requirements
Database: ISOexpresso
Database homepage: http://wiki.tgilab.org/ISOexpresso/
Operating system(s): Microsoft Windows, Linux, or
Mac OS
Programming language: PHP and JavaScript
Other requirements: Apache, PHP, and MySQL
These data are freely available without restrictions for
use by academics.
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Additional file 2: Figure S1. Detailed explanation of the results produced
by the User Data Annotation function for the T>C variant of BTF3L4 (case 2
in Fig. 4b). (PNG 75.3 kb)
Additional file 3: Table S2. Overall landscape of the match and mismatch
between the major and canonical (or principal) isoforms in the 15 cancer
types. (PDF 697 kb)
Additional file 4: Figure S2, S3, and S4. Variability check results in
mutation interpretation using TCGA STAD data. Figure S2. Cases in which
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Figure S3. Cases in which the major isoform does not match the
UniProt-based canonical isoform. Figure S4. Cases in which the major
isoform does not match the APPRIS principal isoform. (XLSX 25.2 kb)
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